Novel antidotes for target specific oral anticoagulants

Arundhati Das and Delong Liu

Abstract

Target specific oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban) are changing the landscape of anticoagulation. The major drawback is the absence of an effective antidote for severe bleedings and/or prior to procedures. Currently there are a few promising antidotes undergoing clinical trials. This review summarized the latest development in idarucizumab, andexanet alpha and PER977.

Background

Warfarin, a vitamin K antagonist (VKA), was the only oral anticoagulant for more than half a century [1]. There were various limitations like its narrow therapeutic index, food and drug interactions, need for regular monitoring and frequent dose adjustments. These drawbacks and limitations fuelled the development of newer agents [2]. In 2010, dabigatran, a direct thrombin inhibitor, became the first target specific anticoagulant approved by FDA [3]. It was soon followed by Factor Xa inhibitors-rivaroxaban and apixaban [4, 5]. Edoxaban has most recently joined the rest [6, 7].

They have been approved for prevention of stroke in nonvalvular atrial fibrillation, and recently in prevention of recurrent deep vein thrombosis and pulmonary embolism. These drugs are prescribed in fixed doses and have fewer incidents of intracranial hemorrhage in comparison to warfarin in large randomized phase III studies [8]. Nevertheless bleeding is still a relevant side effect and their biggest drawback has been the lack of a reliable reversible agent [9]. Unlike warfarin, there is no antidote for these newer agents. Currently there are a few promising antidotes undergoing clinical trials. These include idarucizumab, andexanet alpha and PER977 [10].

In this review we summarized studies on antidotes to the target specific oral anticoagulants, their mechanism of action and their potential in changing the future of anticoagulation.

Target specific oral anticoagulants and the risk of bleeding

The development of TSOAs accelerated in the last decade. Various trials comparing warfarin to either dabigatran or any of the Factor Xa inhibitors proved that the newer agents had significantly lower bleeding risk [11, 12]. Ruff et al. did a meta-analysis comparing the safety and efficacy of the four newer oral agents to warfarin in patients with atrial fibrillation. They were found to be equally effective in the prevention of stroke. More importantly the incidence of intracranial hemorrhage was reduced by almost 50 % and there was a significant reduction in all cause mortality. However, an increase in gastrointestinal bleeding was observed [13]. Kham recently reported a case of spontaneous cardiac tamponade within 10 days of starting rivaroxaban on a patient [14]. Certain groups of patients on anticoagulation, such as the elderly with a fall, or those needing emergent surgeries or encountering trauma will need immediate reversal of anticoagulation [15]. This lack of antidote limits the use of TSOAs despite their many benefits.

At present, reversal of TSOAs is usually attempted by the administration of prothrombin complex concentrates (PCC). They contain Factor II, IX and X. The four Factor PCC also contains Factor VII. These agents are supposed to reverse the effect of the novel oral anticoagulants by saturating their action. However this rationale is yet to be proven by studies. Also this method does not neutralize the risk of thromboembolism [16].
**Dabigatran and idarucizumab**

Dabigatran is a direct thrombin inhibitor administered as a low molecular weight prodrug dabigatran etexilate mesylate. After oral administration it converts to dabigatran, which is a reversible inhibitor of activated thrombin. With the RE-LY trial, dabigatran became the first FDA approved oral anticoagulant for the prevention of systemic thromboembolism and stroke in non-valvular atrial fibrillation [17, 18]. Since then there have been noticeable incidents of bleeding. In a recent study comparing the risk of bleeding of dabigatran to warfarin, dabigatran was found to have an increased risk of major bleeding including gastrointestinal bleeds but a lower risk of intracranial hemorrhage [19]. Hemodialysis has been shown to clear 50–60 % of dabigatran and has been used to rapidly reduce massive bleeding [20], but standard hemodialysis is not a practical option in unstable conditions, where continuous venovenous hemodialysis has been successfully used [17, 21].

Idarucizumab (aDabi-Fab, BI 655075, UNII-97RWB5S1U6) is the first dabigatran specific antidote under study. It is a humanized monoclonal antibody fragment [Fab] that binds specifically to dabigatran (Fig. 1). It has an affinity for dabigatran that is ~350 times greater than that of thrombin. In ex vivo studies in rats, steady state dabigatran levels of ~200 ng were completely reversed within 1 min of an intravenous bolus of idarucizumab. Strong similarities were noted in the binding pattern of idarucizumab to dabigatran and thrombin to dabigatran. But idarucizumab lacks thrombin like enzymatic activity and does not bind thrombin substrates. Therefore it does not functionally resemble thrombin [22]. A phase 1, first-in-human, single-rising-dose, randomized, placebo-controlled trial in 110 healthy volunteers (27 placebo, 83 idarucizumab) was conducted to assess the pharmacokinetics, safety and tolerability of idarucizumab [23]. Idarucizumab was found to attain peak plasma levels rapidly. However its concentration decreased to 5 % or less of the peak level within 4 h secondary to renal elimination. It was found that it had to be dosed in 1:1 ratio with dabigatran for its complete efficacy. Also of importance is the fact that it had no impact on the coagulation profile of subjects who received placebo [23]. A phase 3 trial has been ongoing to evaluate the reversal of the anticoagulant effects of dabigatran by idarucizumab in patients treated with dabigatran who have uncontrolled bleeding or require emergency surgeries or procedures (REVERSE AD trial) [24–27]. An interim analysis showed that the anticoagulant effect of dabigatran was completely reversed within minutes by idarucizumab. This interim analysis included 90 patients.

![Fig. 1](image-url)  
**Fig. 1** Idarucizumab binds and inactivates dabigatran. Idarucizumab is the first-in-class dabigatran-specific antidote. It is a humanized monoclonal antibody fragment [Fab] that binds specifically to and inactivates dabigatran.
The primary end point of this study was the maximum percentage reversal of the anticoagulant effect of dabigatran within 4 h after the administration of 5 g of IV idarucizumab. This was determined by measuring the dilute thrombin time (elevated in 68 patients in the analysis) or ecarin clotting time (elevated in 81 patients) at a central laboratory. The median maximum percentage reversal was 100 % (95 % confidence interval, 100–100) in these patients with elevated coagulation profile [28].

**Factor Xa inhibitors and andexanet alfa**

A recent analytical study was conducted in Germany using data from a prospective, noninterventional oral anticoagulation registry. 43 % of the 1776 patients on rivaroxaban reported bleeding and of those 6.1 % were classified as major bleeding [29].

Andexanet alfa (PRT064445, r-Antidote; Portola Pharmaceuticals) is a 39 kDa, recombinant modified decoy of Factor Xa produced in Chinese hamster ovary cells. The amino acid serine is replaced by alanine at position 419. This recombinant protein retains the ability to bind direct FXa inhibitors as well as antithrombin activated by low molecular weight heparin or fondaparinux [30]. There was some concern that it could compete and hinder the function of Factor Xa in an active coagulation thus affecting hemostasis. Andexanet lacks the membrane-binding γ-carboxyglutamic acid domain (Gla domain) of Factor Xa which prevents its binding to the phospholipid membrane of cells (Fig. 2). This property thus allows the activation of Factor Xa by tissue factor and Factor VIIa via the extrinsic pathway [8, 30].

In a preclinical study in a rabbit model, andexanet alfa was found to reverse the action of direct Factor Xa inhibitors in a dose dependent manner [31]. The phase II studies with rivaroxaban and apixaban demonstrated a decrease in activity of Factor Xa by 53 and 20 % respectively. In a phase 2 randomized, double blind, placebo-controlled trial of andexanet, preliminary reports showed that a bolus dose of andexanet α antagonized the anti-Xa activity of apixaban and rivaroxaban (5 mg twice daily, 11 doses) in healthy subjects [32–35]. At present randomized placebo controlled double-blinded phase 3 trials are ongoing to evaluate the safety and efficacy of andexanet alfa in reversing apixaban- (ANNEXA-A study) and rivaroxaban-(ANNEXA-R study) induced anticoagulation in healthy volunteers.

**Target specific oral anticoagulants and PER977**

PER977 (arapazine, ciraparantag; Perosphere Inc.) is a small, 512 Da, synthetic, water soluble molecule that binds to direct inhibitors of factor Xa and IIa as well as to heparin-based anticoagulants through non-covalent hydrogen bonding and charge interactions. It is reported to antagonize the effects of all anticoagulants except VKAs and agratranob [8, 30].

In an animal model, rats were overdosed with rivaroxaban, apixaban, edoxaban and dabigatran. PER977 was noted to reduce bleeding within 30 min of administration [36].

In the first human trial of PER977 (NCT01826266), the pharmacokinetics and pharmacodynamics were studied
with escalating doses of PER977 (100–300 mg). It was tested on volunteers who were either untreated or pre-treated with 60 mg of edoxaban. A dose of intravenous bolus of 300 mg PER977 was found to normalize whole blood clotting time within 10–30 min and the effect was sustained for over 24 h [37].

Conclusion
Target specific oral anticoagulants represent a new era in anticoagulation. The major drawback is the absence of an effective antidote. With the ongoing clinical trials and preliminary results from the trials [28, 37], effective antidotes that can successfully reverse the effects of these novel anticoagulants may become available in the near future.

Authors’ contributions
DL designed the study. AD and DL drafted the manuscript. Both authors read and approved the final manuscript.

Author details
1 Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA. 2 Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.

Acknowledgements
This study was partly supported by Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.

Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.

Received: 20 July 2015   Accepted: 25 August 2015
Published online: 15 September 2015

References
1.   Mueller RL, Scheidt S. History of drugs for thrombotic disease. Discovery, development, and directions for the future. Circulation. 1994;89(1):432–49.
2.   Robert F: The potential benefits of low-molecular-weight heparins in cancer patients. J Hematol Oncol. 2010;3:3.
3.   Redondo S, Martinez MP, Ramajo M, Navarro-Dorado J, Barez A, Tejerina T. Pharmacological basis and clinical evidence of dabigatran therapy. J Hematol Oncol. 2011;4:53.
4.   Arepally GM, Ortel TL. Changing practice of anticoagulation: will targeted specific anticoagulants replace warfarin? Annu Rev Med. 2015;66:241–53.
5.   Mega JL, Simon T. Pharmacology of antithrombotic drugs: an assessment of oral antplatelet and anticoagulant treatments. Lancet. 2015;386(9990):281–91.
6.   Buller H, Investigators H-V. Enoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406–15.
7.   Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.
8.   Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. Thromb Haemost. 2015;113(5):931–42.
9.   Siegal DM, Garcia DA, Crowther MA. How I treat target-specific oral anticoagulant—associated bleeding. Blood. 2014;123(8):1152–8.
10.   Bauer KA. Targeted anti-anticoagulants. N Engl J Med. 2015;373:569–71.
11.   van Es N, Coppens M, Schumal S, Middeldorp S, Buller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014;124(12):1968–75.
12.   Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Woydyla DM, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE Trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol. 2014;63(20):2141–7.
13.   Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.
14.   Kham NM, Song M. Spontaneous, life-threatening hemorrhagic cardiac tamponade secondary to rivaroxaban. Am J Ther. 2015;22 PMID 26053030.
15.   Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014;35(28):1864–72.
16.   Honickel M, Treutler S, van Ryn J, Tillmann S, Rossaint R, Grotte K. Reversal of dabigatran anticoagulation ex vivo: porcine study comparing prothrombin complex concentrates and idarucizumab. Thromb Haemost. 2015;113(6):728–40.
17.   Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation. 2011;123(13):1436–50.
18.   Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.
19.   Fernandez I, Baik SH, Fihera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2015;175(1):18–24.
20.   Warkentin TE, Margotts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW. Recombinant factor Vlla (rFVlla) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood. 2012;119(9):2172–4.
21.   Paul S, Hamouda D, Prashar R, Mbasso C, Khan A, Ali A, et al. Management of dabigatran-induced bleeding with continuous venovenous hemodi-lysis. Int J Hematol. 2015;101(6):594–7.
22.   Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121(18):3554–62.
23.   Gland S, Moschetti V, Norris S, Stangier J, Schmohl M, van Ryn J, et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost. 2015;113(5):943–51.
24.   Pinto I, Giri A, Arshad U, Gajra A. New Oral Anticoagulants and Their Reversal. Curr Drug Saf. 2015;10 PMID 25877809.
25.   Pollack CV. New oral anticoagulants in the ED setting: a review. Am J Emerg Med. 2012;30(9):2046–54.
26.   Pollack CV. Coagulation assessment with the new generation of oral anticoagulants. Emerg Med J. 2015;32: doi:10.1136/emermed-2015-204891.
27.   Pollack CV, Reilly PA, Bernstein R, Dubiel R, Eikelboom J, Gland S, et al. Design and rationale for RE-VERSE AD: a phase 3 study of idaruci-zumab, a specific reversal agent for dabigatran. Thromb Haemost. 2015;114(1):198–205.
28.   Pollack CV, Reilly PA, Eikelboom J, Gland S, Verhamme P, Bernstain RA, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–20.
29.   Beyer-Westendorf J, Förster K, Pannach S, Ebertz F, Gelbricht V, Thiene C, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014;124(6):955–62.
30.   Gomez-Outes A, Suarez-Gea ML, Lecumberri R, Terleira-Fernandez AI, Vargas-Castrillon E. Specific antidotes in development for reversal of novel anticoagulants: a review. Recent Pat Cardiovasc Drug Discov. 2014;9(1):2–10.
31.   Lu G, DeGuzman FR, Hellenbach SJ, Karbarz MJ, Abe K, Lee G, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19(4):446–51.
32.   Crowther M KM, Lorenz T, Mathur V, Lu G, Hutchaleelaha A, et al. A phase 2 randomized, double-blind, placebo-controlled trial of FRT064445, a
novel, universal antidote for direct and indirect factor Xa inhibitors. J Thromb Haemost. 2013;11(Suppl 2): AS20.1.

33. Crowther M LG, Lu G, Conley PB, Castillo J, Hollenbach S, et al. Reversal of enoxaparin-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for direct and indirect FXa inhibitors—a phase 2 randomized, double-blind, placebo-controlled trial. J Thromb Haemost. 2014;12(Suppl 1): COA01 (abstract).

34. Crowther M LG, Conley P, Hollenbach S, Castillo J, Lawrence, J, et al. Sustained reversal of apixaban anticoagulation with andexanet alfa using a bolus plus infusion regimen in a phase 2 placebo controlled trial. Eur Heart J 2014;35(Suppl.1): P738 (abstract).

35. Crowther MMV, Kitt M, Lu G, Conley PB, Hollenbach S, et al. A phase 2 randomized, double blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for FXa inhibitors. Blood. 2013;122(21):3636.

36. Bakhru S, Laulicht B, Jiang X, Chen L, Pan D, Grosso M, et al. PER977: a synthetic small molecule which reverses over-dosage and bleeding by the new oral anticoagulants. Circulation. 2013;128:A18809.

37. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371(22):2141–2.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit